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Abstract
Emphysematous pyelonephritis is an acute necrotizing infection 
with gas in the kidney and perinephric space that carries a bad 
prognosis. Apart from its predisposing clinical entities, diabetes mel-
litus and immune-incompetence are quite common in patients with 
this infection. We report a case of a 53-year-old kidney transplant 
recipient diabetic male, suffering from recurrent fever, abdominal 
pain and nausea episodes. Immediate broad-spectrum antibiotics 
were administered and percutaneous drainage was performed after 
the diagnosis. The bacteria involved were Stahpylococcus epider-
midis and Escherichia coli. After 4 weeks of antibiotic treatment 
and abscesses drainage, the case was resolved. Consecutives urine 
cultures and ultrasonographies confirm the complete resolution of 
the disease. We discuss the predisposing factors, clinical presenta-
tion and management.
Introduction 
Emphysematous pyelonephritis is a severe necrotizing infec-
tion of the renal parenchyma. The main causal agent is 
gas-forming bacteria like Escherichia coli, Klebsiella pneu-
monia or Proteus mirabilis.1-3 The disease may induce fever, 
pain, acute renal failure, septic shock or even death.4 It is 
a rare disease, with a high mortality rate.3,5 Few cases in 
kidney allograft have been reported.6,7 The risk factors are 
poor controlled diabetes, immunosuppression and urinary 
obstruction.5
Treatment for this infection is debatable.1,8 At first, 
nephrectomy combined with intravenous antibiotics was 
considered the preferred treatment.8 Currently, a percuta-
neous drainage combined with intravenous antibiotics has 
been proposed as a possible successful treatment. Over time, 
the condition could worsen and treatment, even surgery, 
would be too late to consider.1
Several classifications with the treatment options have 
been proposed, with no clear conclusion. Therefore, indi-
vidual assessments yield better results.2,4,5,7,8
We report a case of emphysematous pyelonephritis in a 
renal transplant recipient. We also review the other reported 
cases.
Case report
A 53-year-old male with end-stage renal disease secondary 
to insulin-dependent diabetes mellitus suffers recurrent fever 
episodes. He received kidney transplantation 9 years ago. 
His current immunosuppression regimen was sirolimus 4 
mg, mycophenolate mofetil (MM), 500 mg in the morning 
and 250 mg in the evening, and insulin therapy. He had a 
baseline serum creatinine of 1.1 mg/dL after kidney trans-
plantation and poorly controlled blood glucose with gly-
cosylated hemoglobin 8.3%. A percutaneous transluminal 
coronary angioplasty (PTCA) was performed 10 years ago 
due to a 90% ischaemic injury requiring a coronary stenting. 
He is a smoker, suffers hypertension and diabetes mellitus. 
On follow-up by a cardiologist none relevant findings were 
highlighted.
He developed an episode of graft pyelonephritis in 
January 2012, from which he recovered after a 2-week 
course of intravenous antibiotics (amikacin and linezolid) 
to a serum creatinine (SCr) of 1.7 mg/dL. No instrumenta-
tion of the urinary tract had been performed prior to this 
episode. A graft ultrasound has been done yearly, with no 
evidence of stones or obstruction in the urinary system. The 
urine culture showed Staphylococcus epidermidis and E. coli 
growth. The repeat urine culture done 2 weeks later did not 
reveal any growth.
Four months later, the patient request medical assessment. 
He had episodic fever with recent nausea and vomiting. No 
urinary symptoms were reported. He had deteriorating gen-
eral health and weight loss was evident. At examination, 
tender graft was observed at palpation. No rise of tempera-
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ture was measured, his heart rate and blood pressure were 
within normal range (70 bpm, 130/85 mmHg). The laboratory 
analysis showed elevated serum creatinine of 3.2 mg/dL, a 
hemoglobin level of 7.5 mg/mL, an elevated C-reactive pro-
tein which reach a maximum of 6.7 mg/L and a total leukocyte 
count of 12000/μL. Although his blood sugar was 100 mg/dL 
at this time, glycosylated hemoglobin was increased which 
implied poorly controlled diabetes mellitus. His immunosup-
pression regimen was not modified and he complied with it. 
His sirolimus levels were desirable (10 ngr/mL).
He was admitted to hospital so that we can begin investi-
gations and to start antibiotic treatment. Two packed erythro-
cytes were transfused and broad-spectrum intravenous anti-
biotics were initiated. We performed an abdomen computed 
tomography (CT) scan, which revealed multiple abscesses, 
gas in parenchyma and collecting system (Fig. 1, Fig. 2), 
with no signs of obstruction or stones. We diagnosed the 
patient with emphysematous pyelonephritis. An ultrasound-
guided percutaneous aspiration was performed and found 
purulent material with Stahpylococcus epidermidis isolated 
on culture. We placed a drainage catheter of 6 cm over the 
bigger abscess for 25 days.
The intravenous antibiotic treatment was linezolid 
(600 mg) twice a day for 1 week and ertapenem 1 g per 
day for 1 month, according to the sensitivity of the micro-
organism. Two consecutive urine cultures were positive for 
Escherichia coli. Although the patient had hypertension, his 
blood pressure remained well-controlled. It was difficult, 
however, to keep his blood sugar under control; it went from 
100 to 244 mg/dL with isolated levels of 300 to 400 mg/
dL in 3 days. Immunosuppression therapy was modified, 
decreasing the sirolimus to 3 mg. Sirolimus levels slightly 
fluctuated between 11.8 and 6.16 ng/mL.
Hematogenous spread was not suspicious due to recent 
tests and uncontrolled blood glucose. The cardiologist per-
formed electrocardiograms which were normal and echocar-
diogram yearly, which showed a left ventricular hypertrophy 
with an ejection fraction of 0.6 and which remained stable 
for years. No more episodes of fever were measured after 
admission. Since the disease started, the patient suffered a 
weight loss of 10 kg and reactive arthritis in his left wrist. 
The patient was discharged after 11 days. 
Antibiotic treatment with sulfamethoxazole/trimethoprim 
(800/160 mg) 3 times a day was maintained for another week 
after the 1-month of ertapenem treatment. Ultrasonography 
tests were performed weekly. A decrease in the abscess size 
(from 6 to 4 cm) was observed until its disappearance 3 
weeks later. Another smaller abscess of 2.8 cm was observed 
without variation in its size. Urine cultures were taken week-
ly for 4 weeks and 3 months later without positive result.
emphysematous pyelonephritis in kidney allograft
Fig. 1. A computed tomography scan shows the kidney allograft in the right iliac 
fossa with two abscesses on upper pole and gas in parenchyma.
Fig. 2. An early follow-up computed tomography scan shows a decrease of 
abscesses and two drainage tubes.
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After 9 months, with regular follow-up every 3 months, 
the patient did not report any fever. His serum creatinine was 
stable at 1.5 mg/dL, his urine cultures were negative and the 
graft ultrasound performed did not show residual abscesses.
Discussion 
Emphysematous pyelonephritis is an extremely rare disease 
in kidney allografts. It is an acute suppurative infection due 
to a gas-forming bacteria.5 Patients with high tissue glucose 
levels, impaired tissue perfusion and defective immune 
response are more likely to suffer a renal parenchyma and 
perirenal tissue infection.4,5 Tissue necrosis is observed and 
could lead to a life-threatening situation.1,8 
Emphysematous pyelonephritis should be suspected in 
immunosuppressed patients or in patients with abnormal 
immune response, inadequate tissue perfusion, or poorly 
controlled diabetics.2,4,5 Females are more likely to suffer a 
emphysematous pyelonephritis; although in renal transplan-
tation, males are more likely to suffer.5,6
Another issue to consider is the urinary tract. Patients with 
obstructive uropathy are more readily to have this infection, 
and a more severe one. This is due to increased tissue pres-
sure and compromised local perfusion.8 Anatomic abnor-
malities must be dismissed too.4
The most important pathogenic micro-organisms related 
to emphysematous pyelonephritis are gas-forming bacte-
ria and those with anaerobic metabolism. More than half 
of pathogens are Escherichia coli (50%8 or 60%-70%),4 
Klebsiella pneumonie (17%8 and 20%-30%4). In our case, 
Staphylococcus epidermidis was isolated in the urine culture 
together with Escherichia coli.
The typical presentation of emphysematous pyelonephri-
tis includes fever in 80% of cases with flank or abdominal or 
back pain in 70%, and acute renal failure or defined septic 
shock appear in one-third of cases.4 Urine test and culture 
and blood test usually show at least leukocytosis, increased 
c-reactive protein and pyuria.1 Although transplanted 
patients may cloud, reduce or confuse some symptoms, an 
imaging test would guide our diagnosis. The first approach 
is ultrasonography, showing gas in renal or perinephric tis-
sue with dirty shadowing,5 but the definitive diagnosis test 
is an abdomen CT.3 It allows us to assess the extent of renal 
parenchymal involvement and to determine the patient’s 
response to therapy.9
The most controversial point of this pathological entity 
is its management. Early nephrectomy and joint antibiotic 
therapy were the standard treatment.5,8 Now there is a trend 
to maintain a conservative treatment regimen by percutane-
ous techniques. A percutaneous drainage proposed in criti-
cal patients or in patients with a solitary kidney or severe 
chronic renal insufficiency showed a successful rate of 18% 
to 80%.8 Early nephrectomy is associated with higher mortal-
ity rates than initial conservative treatment. A 25% mortal-
ity rate was observed in patients undergoing an emergency 
nephrectomy, 50% in medical management, and only 13% 
in percutaneous nephrostomy and medical management.6 
Imaging follow-up is mandatory and especially useful if the 
patient’s condition worsens or deteriorates.
To simplify the management of emphysematous pyelo-
nephritis, a few options have been proposed. The one most 
used was made by Huang and Tseng.10 It is based on CT find-
ings and 4 classes, in which a kidney transplantation patient 
will always be in class 4 and would require a nephrectomy.5 
Wan and colleagues propose another classification divided 
into 2 types. It is more simple and the real challenge is to 
achieve a conservative management in patients in the type 
2 classification (with collections on renal/perirenal tissue 
with gas in the collecting system).7 Three classification stages 
were proposed by Al-Geizawi and colleagues and depend 
on the percentage of gas replacing renal parenchyma, and 
specially focus on renal allograft cases.6
Conclusion 
Emphysematous pyelonephritis is a life-threatening condi-
tion mostly associated with poorly controlled glucose levels. 
A high index of suspicious is required in those patients not 
responding to the routine management of pyelonephritis. It is 
a radiological diagnosis and CT is the best investigation. The 
general status of the patient, a prompt response to antibiotic 
treatment and a proper derivation or no signs of obstruction 
in the urinary tract would indicate the prognosis. The condi-
tion is currently managed with percutaneous drainage, while 
there is still a possible high mortality rate. 
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